trending Market Intelligence /marketintelligence/en/news-insights/trending/7RP6SlJS1u7YXF9H8By_Xw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Amarantus closes licensing deal for therapeutic products with Emerald Organic

Amazon e-commerce sales soar amid COVID-19

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Amarantus closes licensing deal for therapeutic products with Emerald Organic

Amarantus BioScience Holdings Inc. completed its sublicense agreement with Emerald Organic Products Inc. for the rights to its therapeutic products.

Eden Prairie, Maine-based Emerald has received development rights to Amarantus' skincare product engineered skin substitute, cell loss prevention therapy mesencephalic astrocyte-derived neurotrophic factor, and protein discovery platform PhenoGuard.

As part of the deal, Amarantus is receiving an up-front payment of preferred stock in Emerald to be valued at a minimum of $66.6 million and will receive single-digit royalties, with a right to buy into up to double-digit royalties until April 2022.

Amarantus can convert the preferred stock it has received in the agreement to 33,333,333 shares in Emerald in April 2022, before which it can convert the preferred stock when Emerald's shares have maintained an average price above $5 apiece on the average volume of 1 million shares traded for a period of 20 days.

New York-based biopharmaceutical company Amarantus' president and CEO, Gerald Commissiong, will join Emerald's board, while its chief scientific officer, John Commissiong, will become a scientific adviser for the medical cannabis company.

Gerald Commissiong and Elise Brownell, Amarantus' executive vice president of operations and project management, will join Emerald's life sciences division, which Emerald intends to start with its gains in the agreement, said Emerald President and CEO Ian Parker.

The companies are still negotiating a deal for eltoprazine, a potential drug for treating dyskinesia — uncontrolled movement associated with treatment by Parkinson's disease drug Levodopa. The drug is under development by Elto Pharma Inc., Amarantus' joint venture with Psychogenics Inc.